Skip to search formSkip to main contentSkip to account menu

palosuran

Known as: 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea sulfate salt 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (Type 2 DM) is a growing global public health threat, leading to a significant cost burden to society… 
2014
2014
Palosuran Treatment Effective as Bosentan in the Treatment Model of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder that any valuable advance in the management of diseases… 
2012
2012
Effectiveness of Palosuran in Bleomycin-Induced Experimental Scleroderma
Systemic sclerosis (SSc) is a disease characterized by skin and internal organ involvement. There is progressive accumulation of… 
2012
2012
Prolidase Could Act as a Diagnosis and Treatment Mediator in Lung Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with unknown etiology and pathogenesis. With high mortality risks… 
2012
2012
Can Palosuran, as an Urotensin II Receptor Antagonist, Protect Kidneys from Calcineurins: 1681
2011
2011
Urotensin II in the Pathogenesis of Atherosclerosis in Cholesterol Fed Rats
Background: Atherosclerosis is the most common cause of ischemic heart diseases. Urotensin II is the most potent vasoactive… 
2007
2007
Der Urotensin II Rezeptorantagonist Palosuran senkt den Pfortaderdruck durch eine Aktivierung des mesenterialen RhoA/Rho-kinase-Signalweges in der Leberzirrhose
2006
2006
Palosuran in patients with macroalbuminuria and diabetes
  • 2006
  • Corpus ID: 195108016
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)